Extensive characterization of EGFR and of its downstream pathways may help integrating the use of EGFR-targeted therapies in patients.
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Background. Squamous cell anal cancer (SCAC) is a rare disease, 
representing 1.5% of all the gastrointestinal tumors. Patients with SCAC are 
traditionally managed with chemoradiation therapy. When non-response or 
recurrence occur, abdominoperitoneal resection of the anal canal is 
recommended. New therapeutic options are wondered to overcome the 
severe side effects of this surgical procedure. 
It has been demonstrated that the majority of SCAC (55-100%) are 
characterized by EGFR (Epidermal Growth Factor Receptor) deregulation.  
Recently, the anti-EGFR monoclonal antibody cetuximab has been FDA and 
EMA approved for the treatment of head and neck squamous cell cancer and 
metastatic colorectal cancer (mCRC). Only sporadic studies investigated the 
use of cetuximab in SCAC, reporting activity in very few patients. 
To date, in SCAC little is known about EGFR and EGFR-downstream 
members alterations, which are well characterized predictive markers of anti-
EGFR therapies efficacy (i.e.: EGFR gene copy number gain) or impairment 
(KRAS, BRAF and PIK3CA mutations) in patients affected by mCRC. 
The aim of this study was to extensively characterize EGFR, KRAS, BRAF 
and PIK3CA alterations in a series of patients with SCAC. 
Patients and Methods. We centrally investigated a cohort of 93 SCAC 
patients diagnosed between 1997 and 2010. Formalin-fixed paraffin-
embedded tissue samples were collected from the Departments of Pathology 




evaluated by fluorescence in situ hybridization (FISH) using the LSI 
EGFR/CEP7 dual colour assay. HPV detection was performed using the 
INNO-LiPA HPV genotyping extra amp kit. Hot-spot mutations in KRAS 
(exons 2 and 3), BRAF (exon 15) and PIK3CA (exons 9 and 20) genes were 
investigated by direct sequencing. 
Results. EGFR gene copy number gain (FISH+) was found in 33/90 (37%) 
evaluable patients. HPV infection was revealed in 87/91 (96%) patients; the 
majority of them (79/87=91%) carried high-risk HPV types. KRAS gene 
mutations were found in 4/91 (4%) analyzable patients. BRAF gene was 
always wild-type (wt). PIK3CA gene mutations were found in 13/89 (15%) 
analyzable cases (10 mutations occurred in exon 9 and 3 in exon 20). No 
patient showed concomitant mutations in KRAS and PIK3CA genes. Among 
33 FISH+ cases, 3 (10%) patients showed a mutation in KRAS gene and 3 
(10%) patients showed a mutation in PIK3CA exon 9.  
Conclusion. In addition to EGFR gene deregulation, KRAS and PIK3CA 
mutations are involved in SCAC carcinogenesis. Considering studies on 
mCRC demonstrating that a EGFR FISH+/ KRAS wt/PIK3CA wt or exon 9 
mutated status is associated with clinical benefit from cetuximab, it can be 
hypothesized that a subgroup of patients affected by SCAC (approximately 
33%) might have a proficient molecular profile with respect to anti-EGFR 
treatments. Our results, therefore, suggest a possible integration of EGFR-
targeted therapies in SCAC and emphasize the need of molecular analyses 
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Anal canal carcinoma is a relatively rare disease, and its most common 
histological type is squamous cell carcinoma (SCC) (Martin FT. et al, 2009).  
Human papilloma virus (HPV) is considered the major etiologic agent, but 
many other different risk factors have been identified (Frisch M., 2002). 
Despite the increasing numbers of patients with anal cancer, little has 
changed in the paradigm for the treatment and outcome of this disease 
(Uronis HE. et al, 2007). Patients with primary squamous cell anal cancer 
(SCAC) are traditionally managed with chemoradiation, which results in 
complete response (CR) in up to 90% of cases. In non-responders or 
recurrent patients, salvage abdomino-perineal resection (APR)  is 
recommended (Gervaz P. et al, 2008; Czito BG. et al, 2009; Meyer J. et al, 
2010). 
 
1.1 EPIDEMIOLOGY AND RISK FACTORS 
SCAC is a rare tumor and accounts for only 1.5% of cases of gastrointestinal 
tract cancer (Martin FT. et al, 2009). The age-adjusted incidence rate is 1.5 
per 100,000 both in Ticino and in Italy. Of note, the incidence of anal cancer 
is much higher in men who practice anoreceptive intercourse and in those 
with human immunodeficiency virus (HIV). Historically, anal cancer was 
believed to develop as a result of chronic irritation resulting from benign 
conditions, including hemorrhoids and fissures, and there was also thought to 
be an association with inflammatory bowel disease (Frisch M., 2002). Several 




identified other risk factors, including a history of persistent high-risk 
genotype HPV infection, infection with multiple HPV genotypes, cervical 
dysplasia or cancer, HIV seropositivity, low CD4 count, cigarette smoking, 
anoreceptive intercourse, and immunosuppression following solid organ 
transplant (Palefsky JM., 1994; Johnson LG. et al, 2004). 
 
1.2 ANATOMY AND HISTOLOGY 
The anal canal is defined as the terminal part of the large intestine, beginning 
at the upper surface of the anorectal ring and passing through the pelvic floor 
to end at the anus. The most important macroscopic landmark in the mucosa 
is the dentate (pectinate) line composed of the anal valves and the bases of 
the anal columns (Figure 1) (Ryan DP. et al, 2000). 
 















Histologically, the mucosa can be divided into three zones. The upper part is 
covered with colorectal type mucosa. The middle part is the anal transitional 
zone, which is covered by a specialized epithelium with varying appearances; 
it extends from the dentate line and on average 0.5-1.0 cm upwards. The 
lower part extends from the dentate line and downwards to the anal verge 
and has formerly been called the pecten. It is covered by squamous 
epithelium, which may be partly keratinized, particularly in case of mucosal 
prolapse. The perianal skin (the anal margin) is defined by the appearance of 
pigmented skin appendages, immediately surrounding the anal orifice, 
extending laterally to a radius of about 5 cm. There exists no generally 
accepted definition of its outer limit. The term anus refers to the distal 
external aperture of the alimentary tract (Tanum G., 1992). 
The lymphatic drainage varies in different parts of the canal in relation to the 
dentate line. Proximally drainage is to perirectal nodes along the inferior 
mesenteric artery. Lymph from immediately above the dentate line drains to 
internal pudendal nodes and to the internal iliac system. Infra-dentate and 
perianal skin drains to the inguinal, femoral and external iliac nodes (Ryan 
DP. et al, 2000). 
Despite its short length, the anal canal produces a variety of tumor types 
reflecting its complex anatomic and histological structure. Squamous, 
glandular, transitional, and melanocytic components occur at this site, either 
alone, or in combination (Janicke DM. et al, 1996). 
Most anal cancers in Europe and in the United States are SCC. These 
tumors come from the squamous cells that line the anal margin and most of 
the anal canal. SCC of the anal margin (perianal skin) are treated similarly to 




Tumors of the anal margin are usually well differentiated, in contrast to 
SCAC. Grading is subject to inter-observer variability, and considerable 
heterogeneity is seen in larger tumors. High-grade tumors have been thought 
to have a worse prognosis, but this has not been confirmed in multivariate 
analysis (Martin FT. et al, 2009). 
SCAC can be either keratinized or non-keratinized depending on their 
location in relation to the dentate line. Importantly, both keratinizing and non-
keratinizing tumors appear to have similar biology and prognosis (Martin FT. 
et al, 2009). 
A small number of anal cancers are known as adenocarcinomas. These can 
develop in cells that line the upper part of the anus near the rectum, or in 
glands located under the anal mucosa that release their secretions into the 
anal canal. These anal adenocarcinomas behave quite differently from SCAC 
and are treated like rectal carcinomas (Tarazi R. et al, 1994). 
 
1.3 CLINICAL PRESENTATION AND STAGING 
Most patients with SCAC present with rectal bleeding. Diagnosis can be 
delayed because this bleeding is often ascribed to hemorrhoids. Other 
symptoms include rectal pain and/or mass sensation, occurring in 
approximately 30% of patients (Tanum G. et al, 1991). Twenty percent of 
patients have no symptoms at the time of diagnosis (Ryan DP. et al, 2000). 
A tumor–node–metastasis (TNM) staging system for anal cancer has been 
developed by the American Joint Committee on Cancer and the International 
Union Against Cancer (Table 1). Because few tumors are surgically excised, 
the system is based on clinical factors with particular emphasis on tumor 




to sixty percent of patients present with T1–T2 lesions, for which the 5-year 
survival rate is 80–90%. A smaller proportion presents with T4 lesions, which 
have a 5-year survival rate of 50%. The incidence of nodal metastasis is 
approximately 10% at diagnosis but can increase to 60% for T4 lesions 


























Prior to the mid-1980s, the treatment of choice for anal cancer was APR, a 
procedure involving removal of the anus and rectum as well as their draining 
lymph nodes and resulting in a permanent colostomy. The 5-year overall 
survival (OS) rate after APR for anal carcinoma is in the range of 40–70%, 
with worse outcomes for those with larger tumors and nodal metastases 
(Martin FT. et al, 2009). APR is now reserved as salvage therapy for those 
individuals with persistent disease after combined chemoradiation. 
 
1.4.2 Combined Chemoradiation 
Based on prior experience of fluoropyrimidines as radiosensitizers in different 
gastrointestinal malignancies, Nigro and colleagues in 1974 investigated the 
use of preoperative chemotherapy with 5-fluorouracil (5-FU) and mitomycin C 
(MMC) plus radiation therapy (RT) given in doses of 30 Gy in patients with 
SCAC (Nigro ND. et al, 1974). Interestingly, the first three patients treated 
achieved a complete pathologic response on evaluation of postsurgical 
specimens, and this resulted in the concept of anal sphincter preservation 
strategies. Subsequent patients series supported the use of chemoradiation 
protocols for anal sphincter preservation, reserving surgery for instances 
where residual disease persisted after combined modality chemoradiation 
therapy. These series showed 5-year OS of 70% and colostomy-free survival 




These results were followed by several large randomized clinical trials, which 
confirmed the role of combined modality therapy and now form the basis of 
the current standard of care in management of SCAC. 
Two European Phase III randomized clinical trials were conducted in late 
1990s to evaluate the benefits of chemoradiation therapy versus RT alone. At 
the same time, two United States trials looked at the efficacy of different 
chemotherapeutic regimens in chemoradiation protocols in the treatment of 
SCAC (UKCCCR Anal Cancer Trial Working Party, 1996; Flam M. et al, 
1996; Bartelink H. et al, 1997; Ajani JA. et al, 2008). 
The United Kingdom Coordinating Committee on Cancer Research-based 
Anal Cancer (UKCCCR) Trial Working group compared RT alone versus RT, 
5-FU, and MMC in a multicenter clinical trial in 1996 (UKCCCR Anal Cancer 
Trial Working Party, 1996). Five hundred eighty-five patients with stage T1 to 
T4 SCAC, with and without lymph node involvement, were randomized. 
Patients received either 45 Gy of RT in 20 or 25 fractions over 4 to 5 weeks 
(290 patients), or the same regimen of RT combined with 5-FU (1000 mg/m2 
for 4 days or 750 mg/m2 for 5 days) by continuous intravenous (IV) infusion 
during the first and the final weeks of RT and MMC (12 mg/m2) on day 1 of 
the first course (295 patients). Clinical response was assessed at 6 weeks 
after initial treatment. Good responders received an additional boost of 
radiation and poor responders underwent salvage surgery. The main 
endpoint was local-failure rate (6 weeks after initial treatment); secondary 
endpoints were OS and cause-specific survival. Only 577 patients were 
eligible for assessment after randomization. Chemoradiation therapy resulted 
in less local failure rates (36% versus 59%, p0.0001) and decreased 




difference in OS between the two therapies at 36 months (65% versus 58%). 
Investigators concluded that chemoradiation therapy results in better survival 
and tumor control than RT alone (UKCCCR Anal Cancer Trial Working Party, 
1996) 
The European Organization for the Research and Treatment of Cancer 
(EORTC) randomized 110 patients to chemoradiation versus RT alone 
(Bartelink H. et al, 1997). They used 5-FU and MMC (750 mg/m2 and 15 mg, 
respectively, instead of 1000 mg/m2 and 12 mg in the UKCCCR Study). The 
addition of chemotherapy to RT resulted in a significant increase in the 
complete remission rate from 54% for RT alone versus 80% for combined 
modality chemoradiation therapy. Significant improvement in locoregional 
control and colostomy-free survival was noted (p=0.02 and p=0.002, 
respectively). The locoregional control rate improved up to 18% at 5 years, 
wheras the colostomy-free survival at that time increased to 32% with the 
addition of chemotherapy to RT. No significant difference in severe therapy 
related toxicity was noted, although anal ulcers were more frequently 
observed in the combined-treatment arm. The OS rate remained similar in 
both treatment arms. The results of this study supported the UKCCCR trial 
conclusions (Bartelink H. et al, 1997). While United Kingdom investigators 
were establishing the role of chemoradiation therapy in anal canal cancer, in 
North America investigators were concentrating on the evaluation of the need 
for MMC in combined modality therapy. As MMC is not a known 
radiosensitizer and is associated with higher renal, pulmonary, and bone 
marrow toxicities, U.S. investigators designed trials to compare 





The Radiation Therapy Oncology Group (RTOG) randomized 310 patients to 
5-FU plus radiation or 5-FU and MMC plus radiation (Flam M. et al, 1996). 5-
FU was infused at a rate of 1000 mg/m2 IV and MMC at 10 mg/m2 IV. 
Radiation doses ranged from 45 to 50.4 Gy. Post-treatment biopsies were 
positive in 15% of patients in the 5-FU arm versus 7.7% in the MMC arm 
(p=0.135). At 4 years, colostomy rates were lower (9% versus 22%; 
p=0.002), colostomy-free survival higher (71% versus 59%; p=0.014), and 
disease-free survival (DFS) higher (73% versus 51%; p=0.0003) in the MMC 
arm. A significant difference in OS was not observed at 4 years. Toxicity was 
found to be greater in the MMC arm (23% versus 7% grade 4 and 5 toxicity; 
p0.001). From these results, investigators reached the conclusion that 
despite more toxicity, MMC still plays an important role in combined modality 
therapy by reducing local recurrence and colostomy rates (Flam M. et al, 
1996). 
RTOG conducted a multicentre phase III trial comparing 5-FU plus MMC and 
RT versus treatment with 5-FU plus cisplatin and radiotherapy in 682 patients 
with SCAC (Ajani JA. et al, 2008). The MMC group received 5-FU (1000 
mg/m2 on days 1 to 4 and 29 to 32) plus MMC (10 mg/m2 on days 1 and 29) 
and RT (45 to 59 Gy). The cisplatin group received fluorouracil (1000 mg/m2 
on days 1 to 4, 29 to 32, 57 to 60, and 85 to 88) plus cisplatin (75 mg/m2 on 
days 1, 29, 57, and 85) and RT (45 to 59 Gy; start day=day 57). The median 
follow-up for all patients was 2.51 years. The 5-year disease-free and OS 
rate were not significantly different (p=0.17 and p=0.10). However, the 5-year 
locoregional recurrence, distant metastasis, and cumulative colostomy rates 
were significantly better for the MMC-based therapy group compared with the 




hematological toxicity was higher with MMC-based treatment (p<0.001) 
(Ajani JA. et al, 2008). 
The two European trials have shown the superiority of chemoradiation over 
RT alone, whereas the two U.S. trials have endorsed the use of MMC in 
combined modality therapy, which significantly reduced local recurrence and 
colostomy rates, despite a higher toxicity rate. The authors concluded that 
MMC was an important part of combined chemoradiation for SCAC and this 
regimen has remained the standard of care. 
 
1.4.3 Treatment Complications 
Chemoradiation therapy for SCAC can have both acute and chronic effects. 
Acute effects include diarrhea, mucositis, skin erythema and desquamation, 
and myelosuppression. Late complications, some of which necessitating 
surgery with or without colostomy, include anal ulcers, stenosis, fistulae, and 
necrosis. Reported late event rates following chemoradiation therapy for anal 
cancer are in the range of 3–16% (Clark MA. et al, 2006). The risk for these 
complications increases as a function of both total radiation dose and fraction 
size, with complications more frequent when fractions >2.5 Gy are used 
(Nigro ND. et al, 1983). As mentioned before, the UKCCCR trial failed to 
demonstrate a higher incidence of late effects with the use of combined 
chemoradiation compared with RT alone (UKCCCR Anal Cancer Trial 
Working Party, 1996). There is one study in the literature that specifically 
evaluates quality of life (QOL) after radiation alone or combined 
chemoradiation (Allal AS. et al, 1999). Allal and colleagues evaluated QOL in 
41 patients (35 female and 6 male) who were alive at least 3 years after 




with RT with or without chemotherapy rated their QOL similar to that of the 
general population, with the exception of noting more frequent diarrhea. 
Interestingly, 50% of patients reported suboptimal anal function, whereas 
71% reported that they were satisfied with their current function and only 7% 
would have considered APR as a potential alternative. 
 
1.5 PERSISTENT OR RECURRENT DISEASE 
Effects of chemoradiation on SCAC can be present after completion of 
treatment. Response is best assessed at least 6–8 weeks after completion. 
There is currently no consensus as to whether response should be assessed 
by physical examination alone or in combination with biopsy. It is also not 
clear whether biopsy should play a role in the management of those 
individuals with a CR. 
There are few data available about predictors of local failure, but one 
retrospective study was identified (Renehan AG. et al, 2005). Renehan and 
colleagues evaluated outcomes of 254 patients with SCAC treated with either 
RT alone (n=127) or combined chemoradiation (n=127) between 1988 and 
2000 at a hospital in the United Kingdom. Local failure occurred in 99 (39%) 
patients and the median time to failure was 20.4 months. Five-year local 
disease failure rates were significantly different between those patients 
receiving RT alone (52.5%) and those patients receiving combined 
chemoradiation (35.3%). For patients receiving RT alone, age, total radiation 
dose >50 Gy and higher T stage predicted local failure. Conversely, for 
patients receiving combined chemoradiation, no factor was predictive 





1.5.1 Salvage APR 
The preferred treatment for persistent disease following combined modality 
therapy is APR. This surgery is radical and associated complications appear 
to be greater in patients undergoing the procedure after combined modality 
therapy (Clark MA. et al, 2004). Nilsson and colleagues retrospectively 
evaluated the outcomes of 35 Swedish patients (21 with persistent disease 
and 14 with recurrent disease) undergoing salvage APR following 
locoregional failure after combined modality therapy for SCAC (Nilsson PJ. et 
al, 2002). Thirteen patients developed perineal wound infection necessitating 
reoperation, and delayed wound healing (defined as healing time >3 months) 
occurred in 23 patients. Fifteen patients, 12 of whom underwent salvage APR 
for persistent disease, experienced secondary failure. The median survival 
duration after secondary failure was 19 (range, 1–78) months. In the 
UKCCCR trial, there were 29 patients who underwent salvage APR; 40% 
eventually relapsed (UKCCCRAnal Cancer Trial Working Party, 1996). 
 
1.5.2 Salvage Chemoradiation Therapy 
Salvage chemoradiation therapy for persistent disease has also been 
evaluated (Flam M. et al, 1996). In the Intergroup study evaluating the role of 
MMC, those patients with persistent disease received salvage 5-FU, 
cisplatin, and 9 Gy of external beam RT (EBRT). Of 29 patients treated in this 
manner, 10 continued to have persistent disease. Nine of these patients went 







1.6 METASTATIC DISEASE 
Metastatic disease develops in 10–17% of patients treated with 
chemoradiation therapy (UKCCCR Anal Cancer Trial Working Party, 1996; 
Bartelink H. et al, 1997). The most common site of distant metastasis is the 
liver. There are limited published data on the use of chemotherapy, 
particularly newer agents, to treat metastatic SCAC. Active agents include 
cisplatin plus 5-FU (Khater R. et al, 1986; Jaiyesimi IA. et al, 1993), 
carboplatin (Evans TR. et al, 1993), doxorubicin (Fisher WB. et al, 1978), and 
semustine (Zimm S. et al, 1981). Participation in a clinical trial should be 
discussed with all potentially eligible patients.  
 
1.6.1 Targeted Therapy 
Because of the high cure rate of localized anal cancers from combined 
modality therapies, little is known for the treatment of patients who progress 
to have metastatic disease. 
In searching for new therapeutic options for these forms of SCAC, and on the 
basis of activity demonstrated in other cancers with similar histology, targeted 
therapies with biological drugs have been recently considered.  
Previously reports have supported the effective use of the EGFR-inhibitors 
cetuximab and panitumumab, two monoclonal antibodies (MoAbs) directed 
against the ligand binding domain of the epidermal growth factor receptor 
(EGFR), in colorectal (CRC) and non-small cell lung cancers (NSCLC) (Van 
den Eynde M. et al, 2011). In particular, for squamous cell variants, in 2006 
cetuximab was approved by the Food and Drugs Administration (FDA) and 
by the European Medicine Agency (EMA) for the treatment of locally 




combination with RT) and of recurrent/metastatic HNSCC (as single agent), 
after failure of platinum-based chemotherapy (Tejani MA. et al, 2010). 
In addition, it has been shown that the inhibition of EGFR signaling is able to 
sensitize cells to radiation in HNSCC, supporting the use of cetuximab in 
combination with RT (Koukorakis G. et al, 2009; Dequanter D. et al, 2010).  
Only few studies reported about the use of cetuximab in chemo-refractory 
patients with advanced SCAC (Phan LK. et al, 2007; Lukan N.et al, 2009; De 
Dosso S. et al, 2010; Saif M. et al, 2011). All these authors evidenced 
excellent response to cetuximab or panitumumab in a total of twelve patients 
with metastatic SCAC, after failure of cisplatin-based regimens. 
The comprehension of biological mechanisms at the basis of cetuximab 
activity, especially concerning EGFR and the members of its downstream 
pathway, which are known to impair the efficacy of anti-EGFR therapies in 
metastatic CRC and in NSCLC, could help in a better identification of patients 
groups who can really benefit from this targeted therapy approach (Mao C. et 
al, 2009; Bardelli A. et al, 2010). 
 
1.7 MOLECULAR BIOLOGY 
SCAC shows a pattern of protein expression/gene deregulation similar to 
those observed in SCC arising in different organs (Holly EA. et al, 2001; 
Zhang J. et al, 2005). Only sporadic reports on the molecular biology of 
SCAC are currently available and most include fewer than 50 patients 
(Gervaz P. et al, 2006). 
Current evidence suggests that HPV infection is necessary, but not sufficient, 
to promote progression of anogenital epithelium towards invasive cancer 




heterozygosity or epigenetic silencing through promoter hypermethylation of 
several tumor suppressor genes (Muleris M. et al, 1987; Heselmeyer K. et al, 
1997; Gervaz P.et al, 2001; Gervaz P. et al, 2006).  
Epidemiologic data have shown that human HIV infected patients are at 
highest risk of SCAC development (Gervaz P. et al, 2004).  
 
1.7.1 HPV  
HPV genome is a 8 kb circular double-stranded DNA (Figure 2). It has two 
regulatory proteins (called early proteins) E1 and E2, three important 
oncogenes with growth-stimulating and transforming properties E5, E6 and 
E7, and two capsid proteins (called late proteins) L1 and L2. The oncogenes 
E6 and E7 are responsible for malignant transformation of infected cells and 
have been used by investigators to induce immortality in cell-lines and cell 
culture models. These two genes cause inactivation of two important tumor 
suppressor proteins: p53 and retinoblastoma (Dyson N. et al, 1989; Crook T. 














The L1 protein has been used to develop the HPV vaccine since it is the 
most conserved gene within the HPV genome.  
HPV is a highly diverse group of viruses, ubiquitous in nature, with world-
wide distribution. HPV has been detected from apparently normal skin and 
appears to have a highly variable latent period before detectable pathology 
(Antonsson A. et al, 2003). HPV is associated with lesions ranging from 
benign cutaneous warts, to recurrent laryngeal papillomatosis, to 
malignancies like cervical and anal cancers (Goon P. et al, 2008). Low- risk 
(LR) HPV types 6 and 11 are the most common HPV associated with genital 
warts and most cases of recurrent respiratory papillomatosis. High-risk (HR) 
HPV types 16 and 18 are most commonly associated with dysplasia.  
HPV infection has a high prevalence in sexually active population, yet most 
patients infected with HR HPV do not develop cancer. It has been reported 
that HR HPV is detected in 80-100% of anal cancer cases, and all various 
infected cases were shown to have integrated viral DNA (Holm R. et al, 1994; 
Gervaz P. et al, 2006). As HPV was detected in all phases of SCAC 
development (from anal intraepithelial neoplasia to invasive cancer), it has 
been suggested that HR oncogenic HPV subtypes represent the initiating 
event in anal epithelial transformation (Gervaz P. et al, 2006). 
 
1.7.2 EGFR 
EGFR gene (also known as erbB1, HER1), located on the short arm of 
chromosome 7 (7p12), encodes for a glycoprotein of 170 kDa that consists of 
an extracellular receptor portion, a transmembrane region, and an 
intracellular domain with tyrosine kinase (TK) activity. EGFR binds several 




ligand binding, EGFR can homodimerize or heterodimerize with other 
members of EGFR family (erbB2/HER2, erbB3/HER3, erbB4/HER4) 
triggering a cascade of events implicated in a wide range of cell functions, 
such as cell proliferation, migration, maturation and differentiation (Figure 3). 
EGFR-downstream signal transduction pathways are mainly represented by 
the RAS/RAF/MEK/ERK (MAP kinases) and the PI3K/PTEN/AKT pathways 














EGFR activation and downstream signalling cascade (source: http://commons.wikimedia.org/ 
wiki/File:EGFR_signaling_pathway.svg).  
 
In cancer cells, EGFR receptor has been found to be either overexpressed 
on the membrane either mutated in the sequence coding for the TK domain 
(exon 18-21). These alterations result in a constitutive activation of EGFR, 




of downstream signal transduction pathways, leading to tumor growth, 
metastasis, angiogenesis and inhibition of apoptosis (Baselga J., 2001). 
EGFR is deregulated in a variety of solid malignant tumors (i.e. NSCLC, 
metastatic CRC, HNSCC), including SCAC, and is usually associated with 
disease progression and poor prognosis (Alvarez G. et al, 2006).  
Given the myriad of downstream effects, its frequency of alteration and its 
correlation with prognosis, various approaches have been considered to 
inhibit EGFR, and, consequently, to inactivate its downstream pathways. 
These include gefitinib and erlotinib, two small molecules able to bypass the 
plasma-membrane and to bind to the TK mutated domain, and cetuximab 
and panitumumab, two MoAbs that bind to the extracellular domain. TK 
inhibitors (TKIs) are effective in patients with NSCLC and with locally 
advanced or metastatic pancreatic cancer, while MoAbs received FDA 
approval for the treatment of patients with locally advanced or metastatic 
HNSCC and CRC (Laskin JJ. et al, 2004; Baselga J. et al, 2005). 
The deregulation of EGFR in SCAC has been investigated in very few works, 
with less than 50 investigated patients. 
At protein level, EGFR overexpression has been detected by 
immunohistochemistry (IHC) in the great majority of cases. Authors used the 
same primary antibody (anti-EGFR mouse monoclonal IgG1 antibody) but 
different antigen-retrieval protocols, and observed EGFR positivity in 55% 
(21/33), 83% (36/43) and 100% (21/21) of SCAC patients, respectively (Le 
LH. et al, 2005; Alvarez G. et al, 2006; Van Damme N. et al, 2010). 
At genetic level, EGFR was investigated by fluorescence in situ hybridization 
(FISH) in only two studies. Both reported an increase in EGFR gene copy 




and in 39% (7/18) of SCAC patients, respectively. Gene amplification has 
never been reported (Alvarez G. et al, 2006; Van Damme N. et al, 2010).  
No correlation between EGFR protein overexpression as detected by IHC 
and gene copy number as detected by FISH has been revealed (Alvarez G. 
et al, 2006; Van Damme N. et al, 2010). 
At sequence level, no mutation has been found in exon 18 to 21 of EGFR TK 
domain (in a cohort of 26 patients) (Van Damme N. et al, 2010). 
The involvement of EGFR may have important therapeutic implications in the 
management of patients with SCAC, especially for those refractory to 
standard therapy. In fact, it has been recently reported that cetuximab in 
combination with irinotecan, is effective in tumor control in very few SCAC 
patients refractory to standard therapies, similarly to the results described in 
HNSCC (Phan LK. et al, 2007; Lukan N. et al; 2009, De Dosso S. et al, 2010; 
Saif MW. et al, 2011). In contrast, the use of TKI in SCAC has never been 
reported. 
 
1.7.3 Members of EGFR downstream pathways  
A rapidly growing body of knowledge has indicated that proliferation in many 
tumors is driven by constitutive activation of signaling pathways downstream 
to EGFR, as discussed before. Such close interactions between these 
pathways may provide escape mechanisms that allow tumors to circumvent a 
pathway that has been pharmacologically blocked. The interlinked RAS–
MAPK and PI3K signaling pathways play an important role in tumorigenesis 
via phosphorylation of various proteins and transcription factors that directly 




It has been recently demonstrated that mutation in KRAS, BRAF, or PIK3CA 
oncogenes are important predictive markers of resistance to cetuximab or 
panitumumab treatment in mCRC. Rare studies investigated these markers 
in SCAC (Patel H. et al, 2007; Lukan N. et al, 2009; Zampino MG. et al 2009; 
van Damme N. et al, 2010). 
 
KRAS. KRAS is a member of the rat sarcoma virus (ras) gene family of 
oncogenes (including HRAS, and NRAS), located on chromosome 12, 
encoding for the guanosine bis/tris phosphate (GDP/GTP)–binding protein 
RAS, that acts as a self-inactivating intracellular signal transducer 
(Raaijmakers JH. et al, 2009). RAS proteins normally cycle between active 
GTP-bound (RAS-GTP) and inactive GDP-bound (RAS-GDP) conformations 
(Figure 4). RAS proteins are activated by guanine nucleotide exchange 
factors (GEFs) which are recruited to protein complexes at the intracellular 
domain of activated receptors. Signaling is terminated when RAS-GTP is 
hydrolyzed to the RAS-GDP inactive complex by GTPase-activating proteins 
(GAPs) (Van Krieken H. et al, 2008; Raaijmakers JH. et al, 2009). After 
binding and activation by GTP, RAS recruits the protein encoded by RAF 
oncogene, which phosphorylates Mitogen-Activated Protein Kinase Kinase-1 
(MAP2K-1) and MAP2K-2, thus initiating the MAPK signaling that ultimately 
leads to the expression of proteins playing important roles in cell growth, 
differentiation, and survival. Under physiological conditions, RAS-GTP levels 
are tightly controlled by the counterbalancing activities of GEFs and GAPs.  
KRAS mutations are one of the most common gene alterations in human 




active GTP-bound form due to defective intrinsic GTPase activity and 













Ras activation. Normal condition on the left. Constitutive activation caused by oncogenic 
point mutations on the right (Van Krieken H. et al, 2008). 
 
Unlike wild-type RAS proteins which are inactivated after a short time, the 
aberrant proteins are able to continuously activate signaling pathways in the 
absence of any upstream stimulation of EGFR/HER receptors. There are a 
limited number of mutations in the KRAS gene, and altogether more than 
90% involve two codons (12 and 13). Of these, the most frequent alterations 
are detected in codon 12 (about 80% of all reported KRAS mutations). 
Codons 12 and 13 somatic missense mutations lead to single amino acid 
substitutions and are generally independent from EGFR mutations (Kosaka 




have also been reported, but these make up less than 10% of mutations 
(Edkins S. et al, 2006).  
In SCAC, KRAS mutations have been described only in 2 out of 7 patients 
with metastatic disease treated with cetuximab (Lukan N. et al, 2009). In 
other two cohorts of unselected SCAC, KRAS was always wild type (i.e. 0/26 
and 0/30 investigated cases, respectively) (Zampino MG. et al 2009; van 
Damme N. et al, 2010). 
 
BRAF. BRAF gene, located on chromosome 7, encodes for a RAS effector 
belonging to the RAF family of Ser-Thr kinase proteins. BRAF gene product 
is recruited to the plasma membrane upon binding to RAS-GTP, and 
represents a key point in the signal transduction through the MAP kinase 
pathway. 
BRAF sequence contains three conserved regions: CR1, that encodes for the 
putative zinc finger domain, CR2, where several Ser-Thr-rich regions are 
located, and CR3, which corresponds to the kinase domain. The two major 
regulatory sites are Thr599 and Ser602, phosphorylated by RAS.  
BRAF is the only RAF protein found to be frequently mutated in cancer. 
Mutations were identified in approximately 50% of melanoma, and in a 
smaller percentage of other tumors, including thyroid, colonic and ovarian 
carcinomas, and some sarcomas (Michaloglou C. et al, 2008). All mutations 
are represented by activating missense point mutations clustered in exons 11 
and 15. In particular, the most common oncogenic BRAF mutation, occurring 
in more than 90% of cases, corresponds to a T>A transversion at position 
1799 of BRAF sequence, resulting in the Valine to Glutamate substitution at 




the phosphorylation of Thr599 and Ser602. This change leads therefore to a 
mutated BRAF protein with elevated kinase activity, able to constitutively 
activate MAPK pathway (Davies H. et al, 2002).  
At the moment, BRAF gene mutations have never been investigated in 
SCAC. 
 
PI3K. Phosphatidylinositol 3-kinases (PI3Ks) belong to the lipid kinases 
family that regulates the signal transduction (Vivanco I. et al, 2002). PI3K 
proteins are constituted by catalytic and adaptor/regulatory subunits variants 
encoded by separate genes, are originated by alternative splicing, and are 
activated downstream of several TK receptors like EGFR, HER2, IGF1R, 
cKIT, PDGFR and MET, that, directly or through adaptor proteins, bind to and 
activate PI3Ks. Activation of PI3Ks results in the production of the second 
messenger phosphatidylinositol (PI) 3,4,5 trisphosphate (PIP3) from PI 4,5 
bisphosphate (PIP2). PIP3, through AKT activation, drives various 
downstream pathways involved in the regulation of several functions 
including cellular growth, transformation, adhesion, apoptosis, survival and 
motility (Yuan TL. et al, 2008).  
PI3Ks are antagonized by the phosphatase PTEN (Phosphatase and TENsin 
homolog deleted on chromosome 10) that catalyzes the opposite reaction. 
Constitutive activation and overexpression of PI3Ks (and inactivation of 
PTEN) results in enhanced PI3K signalling leading to oncogenic cellular 
transformation and cancer. Only PI3K proteins that contain the catalytic 
subunit p110, and its associated regulatory subunit p85, are involved in 
tumorigenesis (Samuels Y. et al, 2010). The p110 subunit is encoded by 




exons and coding for a 124 kDa size protein. Hyperactivating PIK3CA 
mutations have been identified in several tumors, including breast, 
endometrial, urinary tract, ovarian, brain and gastric cancers (Yuan TL. et al, 
2008; Samuels Y. et al, 2010). 
The large majority of PIK3CA mutations cluster in two conserved regions, the 
helical domain, encoded by exon 9, and the kinase domain, encoded by exon 
20. The hotspot mutations E542K and E545K (in exon 9), and H1047R (in 
exon 20), are non-synonymous missense mutations that confer a constitutive 
kinase activity to the protein. Rare mutations may also occur in exons 6 and 
7 (Karakas B. et al, 2006). 
In SCAC, PIK3CA was investigated in only one study. Five coding sequence 
mutations were found out of 127 patients (4%). All were aminoacid 
substitutions: one in exon 9 (E545K) and 4 in exon 20 (3 H1047R and 1 
H1047L) (Patel H. et al, 2007). 
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2 AIM OF THE STUDY 
 
Aim of the present study was to characterize the pathway of EGFR, by 
analyzing EGFR gene status by FISH and KRAS, BRAF and PIK3CA 
mutations by sequencing in a large cohort of SCAC patients, for a possible 
introduction of anti-EGFR MoAb treatments, able to overcome the severe 
effects of ablative surgery in persistent or recurrent disease. 
 
2.1 RATIONALE  
In the era of targeted therapies, novel anti-EGFR biological drugs have 
entered into clinical practice. Anti-EGFR MoAbs, such as cetuximab and 
panitumumab, have been FDA and EMA approved in the treatment of mCRC 
and HNSCC showing efficacy in around 10-30% of patients (Tejani MA. et al, 
2010; Van den Eynde M. et al, 2011). 
It has been recently demonstrated that a proficient molecular profile is 
fundamental in predicting response to anti-EGFR agents. In particular, 
experience in mCRC revealed that EGFR deregulation, both at protein and 
genetic level, is a promising approach to predict response. But, since at the 
moment IHC is not considered suitable for the investigation of EGFR protein 
expression, because many pre-analytical and analytical factors could bias the 
results, and therefore patients selection, FISH seems to be a reliable tool for 
the determination of EGFR gene copy number and the prediction of efficacy 
to anti-EGFR drugs (Atkins D, et al, 2004; Langner C, et al, 2004; Moroni M. 
et al, 2005; Kersting C, et al, 2006; Frattini M. et al, 2007). However, 
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mutations occurring in EGFR-downstream members, such as KRAS, BRAF 
and PIK3CA genes, are able to impair response to anti-EGFR therapy and 
their role in conferring resistance has appeared, at least in mCRC (Moroni M. 
et al, 2005; Lievre A. et al, 2006; Benvenuti S. et al, 2007; Frattini M. et al, 
2007). 
Anecdotic studies investigating the use of the MoAb cetuximab in SCAC 
showed efficacy and disease control in very few patients with advanced and 
refractory forms (Phan LK. et al 2007; Lukan N.et al, 2009; De Dosso S. et al, 
2010; Saifi M. et al, 2011). Unfortunately, deregulation of EGFR and of 
members of its downstream pathways have been poorly characterized in 
SCAC. 
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3 PATIENTS AND METHODS 
 
3.1 PATIENTS 
We retrospectively analyzed a cohort of 93 patients with histologically 
confirmed SCAC. The study was approved by the Institutional Ethical 
Committee of the Institute of Pathology, Locarno, Switzerland. 
Forty-four patients were collected at the Institute of Pathology, Locarno, 
Switzerland, 27 at the University School of Medicine, Novara, Italy, 12 at the 
Civil Hospital, Legnano, Milan, Italy, and 10 at the Medicine Department, 
Modena Hospital, Modena, Italy. 
All histological sections (from biopsies and excisions) were centrally reviewed 
by two expert pathologists who confirmed the diagnoses of SCAC. 
Patients were operated between 1997 and 2010. Sixty-eight (73%) patients 
were female and twenty-five (27%) were male. Age at diagnosis ranged from 
24 to 95 years (median age: 64), with 16 patients (17%) younger than 50 
years, and 6 patients (6%) younger than 40 years. Sample size ranged from 
0.2 cm to 5 cm in diameter (median: 0.7 cm). Considering patients for which 
data were available, 35/82 (43%) were classified as grade (G) 3, 37/82 (45%) 
as G2 and 10/82 (12%) as G1. The majority of tumors (60%) were 
keratinized. 
The clinical-pathological features of SCAC patients are detailed in Table 2. 






























Clinical and histopathological data of investigate SCAC patients. 
 
3.2 MOLECULAR ANALYSES 
All the analyses were performed on formalin-fixed (10% buffered) paraffin-
embedded (FFPE) tumor specimens.  
FFPE tumor blocks were reviewed for quality and tumor content by analyzing 
detailed morphology of haematoxylin and eosin stained tissue sections of 
each blocks. 
A single representative block from each case, containing at least 70% of 
neoplastic cells, was selected for FISH, HPV, and sequencing analyses.  
To minimize cross contamination, the microtome blade was changed and the 
microtome surface was cleaned after each sample was sectioned.  
For HPV and sequencing analyses, tumor macrodissection was performed 
when necessary to minimize the presence of non-neoplastic tissues.  
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3.2.1 HPV analysis 
After deparaffinization, DNA was extracted using the QIAamp Mini kit 
(Qiagen) according to manufacturer’s instructions. 
HPV detection was performed using the INNO-LiPA HPV genotyping extra 
amp kit (Innogenetics). This test is a polymerase chain reaction (PCR)-based 
line hybridization assay that utilizes a cocktail of biotinylated consensus 
primers (SPF10) to amplify a portion of the L1 ORF of 15 HR HPV types (16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), 7 LR HPV types (6, 11, 
40, 43, 44, 54, 70) and 5 probable HR types (pHR, 26, 53, 66, 69/71, 74). 
Four µl of DNA solution (25 ng/µl) was used for the PCR assay in a final 
volume of 25 l using AmpliTaq Gold. PCR reaction consisted of 40 cycles 
(30 sec of denaturation at 94°C followed by 45 sec of annealing at 52°C and 
45 sec of extension at 72°C). The PCR product was then denatured, and a 
10 l aliquot was hybridized on nitrocellulose strips onto which HPV type-
specific oligonucleotides were already bound. After 60 min at 49°C, the PCR 
product bound to a specific probe was detected by an alkaline phosphatase-
streptavidin conjugate and colorimetric detection. The reading of the 
hybridized strips was performed by comparison with standard control strips, 
following standardized criteria (Safaeian M. et al, 2007). 
 
3.2.2 FISH 
EGFR gene status evaluation was realized on 3 µm thick tissue sections that 
were treated using Paraffin Pretreatment kit II (Abbott Molecular) according 
to manufacturer’s instructions. Dual-color FISH assay was performed using 
LSI EGFR/CEP7 probes (Abbott Molecular). The LSI EGFR probe is labeled 
in SpectrumOrange and covers an approximately 300 kb region that contains 
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a 
the entire EGFR gene at 7p12. The CEP7 probe, labeled in SpectrumGreen, 
hybridizes to the alpha satellite DNA located at the centromere of 








Schematic representation of LSI EGFR/CEP7 probe set (Abbott Molecular). A: probes map 
on chromosome 7, B: EGFR probe construction. 
 
Target sections and probes were co-denatured at 75°C for 5 min and allowed 
to hybridize overnight at 37°C. A post-hybridization stringency wash was 
carried out in a water bath at 72°C for 5 min. After washing twice and drying 
at room temperature for 10 min, slides were mounted with 406-diamidino-2-
phenylindole (DAPI II; Abbott Molecular). FISH signals were evaluated with a 
fluorescent automated microscope (Zeiss Axioplan 2 Imaging, Zeiss) 
equipped with single and triple band pass filters. Image for documentation 
were captured using an AxioCam camera (Zeiss Axiocam MRm) and 
processed using the AxioVision system (Zeiss). A minimum of 100 
morphology-clear, non-overlapping nuclei from at least 8-10 different areas 
were scored for each patient.  
For cases in which only a biopsy was available, all the analyzable nuclei 
were evaluated. 
b 
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Patients were classified according to two different approaches, using both 
descriptive criteria (developed on the basis of cytogenetic classification) and 
a scoring system based on gene copy number gain (adopted for EGFR FISH 
interpretation in NSCLC, namely Colorado Scoring System) (Martin V. et al, 
2009; Varella Garcia M. et al, 2009; Martin V. et al, 2012). 
In details, the descriptive criteria were based on the highlighted abnormalities 
and the percentage of cells involved: patients exhibiting one balanced copy 
of EGFR gene and chromosome 7 centromere in >50% of tumor cells were 
classified as loss (loss); patients with two balanced copies of chromosome 7 
in >50% of tumor cells were classified as disomic (D); patients with 3-4 
copies or >4 copies of chromosome 7 in 40% of cells were classified as low 
polysomic (LP) or high polysomic (HP), respectively; patients with a ratio (R) 
EGFR gene/chromosome 7 centromere >2 in 10% of cells were classified 
as EGFR amplified (A). In parallel, patients carrying 4 copies of EGFR in 
40% of cells or gene amplification were considered as FISH positive 
(FISH+), while those with 4 copies in <40% of cells were classified as FISH 
negative (FISH-) (Varella Garcia M., 2006; Martin V. et al, 2009; Varella 
Garcia M. et al, 2009; Martin V. et al, 2012). 
 
3.2.3 Mutational analysis  
After deparaffinization, genomic DNA was extracted using the QIAamp Mini 
kit (Qiagen) according to manufacturer’s instructions. 
KRAS (exon 2), BRAF (exon 15) and PIK3CA (exons 9 and 20) mutations 
were detected by direct sequencing on genomic DNA as already reported 
(Frattini M. et al, 2004 (a); Frattini M. et al, 2007; Di Nicolantonio F. et al, 
2008; Sartore-Bianchi A. et al, 2009; Martin V. et al, 2012). KRAS exon 2 











T (°C) time cycles T (°C) time cycles T (°C) time cycles T (°C) time cycles
50 2' - 50 2' - 50 2' - 50 2' -
95 10' - 95 10' - 95 10' - 95 10' -
95 15' 95 15' 95 30' 95 30'
55 30' 52 30' 56 30' 55 30'
72 30' 72 30' 72 30' 72 30'
72 3' - 72 3' - 72 10' - 72 10' -













includes codons 12 and 13, BRAF exon 15 includes codon 600, PIK3CA 
exon 9 includes codons 542 and 545 and PIK3CA exon 20 includes codon 
1047. All these codons represent sites where the large majority of oncogenic 
mutations occur (Davies H. et al, 2002; Samuels Y. et al, 2004; Frattini M. et 
al, 2004 (b)). The nucleotide sequence corresponding to every exon was 
amplified from tumor-extracted genomic DNA by PCR, purified (Microcon 
YM-50, Millipore) and directly sequenced. Times, temperatures and cycles of 
PCR reactions for each gene are detailed in Table 3. The list of primers used 
for mutational analyses is reported in Table 4. All samples were subjected to 
automated sequencing by ABI PRISM 3130 (Applied Biosystems). All 
mutated cases were confirmed at least twice starting from independent PCR 
reactions. In each case, the detected mutation was confirmed in the 
sequence as sense and antisense strands. Direct sequencing has a 
sensitivity of about 20%. 
 











List of primers used for PCR reactions. 
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3.2.4 Statistical analysis 
The two-tailed Fisher’s exact test was used to calculate p values for the 
association between clinical-pathological and molecular data. The level of 






HPV 6 LR 1
HPV 16 HR 70
HPV 18 HR 2
HPV 26 pHR 2
HPV 31 HR 1
HPV 33 HR 2
HPV 35 HR 1
HPV 45 HR 1
HPV 58 HR 1
HPV 18 HR , 58 HR 1
HPV 11 LR, 16 HR 2
HPV 6 LR, 16 HR, 45 HR 2









4.1 HPV RESULTS 
HPV test was performed on 91 samples. In two cases material was not 
sufficient for the analysis. Almost all patients (87/91, 96%) were positive for 
HPV infection (HPV+), only 4 (4%) patients were negative (HPV-). 
The great majority of cases (79/87, 91%) were HR type, 2 (2%) cases were 
probable HR type, 5 (6%) cases showed a mixed HR and LR type and 1 (1%) 
case was LR. Among HR type, type 16 was predominant (70/81, 86%). 
Remaining patients showed types 18, 31, 33, 35, 45, 58, or a combination of 












HPV types distribution in investigated SCAC patients. LR: low risk HPV, HR: high risk HPV, 




4.2 EGFR FISH RESULTS 
FISH was successful in 90 cases; 3 samples were not suitable for FISH 
analysis due to tissue fixation. Considering the classical cytogenetic 
classification, 4 cases (4%) were considered as A. Of these, three patients 
presented high level of EGFR gene amplification (R>10) with large clusters of 
signals in all cells (Figure 6a), whereas one patient showed a low level of 
amplification (2<R<3) in different cellular foci, corresponding to 50% of cells 
of the entire section. Fifteen cases (17%) were classified as HP, 32 cases 
(36%) as LP, 37 cases (41%) as D (Figure 6b) and 2 cases (2%) as loss 
(Table 6). 
On the basis of gene copy number gain, 33 patients (37%) were grouped as 











EGFR FISH assay on SCAC patients. A: EGFR gene amplification (R>2 between red/EGFR 




























EGFR FISH results by class (conventional cytogenetical classification) and by group (on the 
basis of gene copy number gain). A: amplification, D: disomy, FISH+: patients carrying 4 
copies of EGFR in 40% of cells or gene amplification, FISH-: patients with 4 copies in 
<40% of cells, loss: loss of chromosome 7, HP: high polysomy, LP: low polysomy. 
 
 
4.3 MUTATIONAL ANALYSIS RESULTS 
 
4.3.1 KRAS SEQUENCING 
KRAS analysis was successful in 91 patients; sequences of two patients 
were not evaluable due to poor quality of DNA. 
Mutations in KRAS gene were found in 4 patients (4%) (Table 7). All 
mutations were represented by classical high frequency alterations, the 
G12D change (GGTGaT, GlyAsp) in 3 cases (Figure 7a) and the G12V 
mutation (GGTGtT, GlyVal) in the remaining one.  
 
4.3.2 BRAF SEQUENCING 
BRAF analysis gave analysable results in 90 patients; three patients were not 








4.3.3 PIK3CA SEQUENCING 
PIK3CA sequencing was successful in 89 patients; four patients were not 
evaluable. Mutations in PIK3CA were found in 13 cases (15%) (Table 7). 
Ten mutations occurred in exon 9 and 3 in exon 20. Mutations in exon 9 
involved codon 545 in 7 cases, codon 546 in 2 cases and codon 542 in one 
case. At codon 545 all mutations corresponded to the transition GA in the 
first base of the codon (GAGaAG, GluLys, E545K) (Figure 7b). 
Mutations in codon 546 involved the first base with the substitution CA in 
one case (CAGaAG, GlnLys, Q546K) and CG in another one 
(CAGgAG, GlnGlu, Q546E); at codon 542 the mutation was present in 
the first base (GAAaAA GluLys, E542K). In exon 20, two mutations 
occurred at the classical codon 1047 (CATCgT, HisArg, H1047R) and 










Sequences profiles in SCAC patients. 
A: presence of mutation in KRAS gene: asterisk indicates the G12D change (GGTGaT, 
GlyAsp). 
B: presence of mutation in PIK3CA exon 9: asterisk indicates the E545K change 





3 pts KRAS mut 30 pts KRAS wt
3 pts PIK3CA 
mut ex9
27 pts PIK3CA wt
57 pts FISH-
1 pt KRAS mut 54 pts KRAS wt
7 pts PIK3CA mut ex9
3 pts PIK3CA mut ex 20
























Sequencing results for KRAS, BRAF and PIK3CA genes. Mut: mutation, wt: wild-type. 
 
 
4.4 EGFR AND DOWNSTREAM MEMBERS RELATIONSHIP 
Overall, EGFR-downstream members were altered in 17 patients (18%). No 











Algorithm of comprehensive cytogenetical and molecular results. 
Ex: exon, mut: mutation, n.e.: KRAS not evaluable, pts: patients, wt: wild-type, *: SCAC 





1 D FISH- WT WT  E545K WT
2 D FISH- WT WT WT WT
3 LP FISH+ WT WT WT WT
4 D FISH- WT WT  Q546K WT
5 n.e. n.e. WT n.e. WT WT
6 LP FISH- WT WT WT WT
7 LP FISH- WT WT WT WT
8 D FISH- WT WT WT  H1048Y
9 LP FISH+ WT WT WT WT
10 LP FISH+ WT WT  E545K WT
11 LP FISH- WT n.e. WT WT
12 loss FISH- WT WT WT WT
13 LP FISH- WT WT WT WT
14 LP FISH- WT WT  Q546E WT
15 HP FISH+ WT WT  E545K WT
16 D FISH- WT WT WT WT
17 D FISH- WT WT WT WT
18 D FISH- WT WT WT WT
19 D FISH- WT WT WT  H1047R
20 D FISH- WT WT WT WT
21 LP FISH- WT WT WT WT
22 A FISH+ WT WT WT WT
23 D FISH- WT WT WT WT
24 LP FISH+ WT WT WT WT
25 D FISH- WT WT WT WT
26 HP FISH+ WT WT WT WT
27 D FISH- WT WT WT WT
28 D FISH- WT WT E545K WT
29 HP FISH+ G12D WT WT WT
30 LP FISH+ WT WT WT WT
31 HP FISH+ WT WT WT WT
32 LP FISH- WT WT WT WT
33 D FISH- WT WT WT WT
34 D FISH- WT WT WT WT
35 D FISH- WT WT WT WT
36 D FISH- WT WT WT WT
37 HP FISH+ G12V WT WT WT
38 HP FISH+ WT WT WT WT
39 LP FISH- n.e. n.e. n.e. n.e.
40 D FISH- WT WT WT WT
 PIK3CA EX 9 PIK3CA EX 20# FISH EGFR  KRAS BRAF
Among the 33 FISH+ patients, 6 (18%) patients showed a mutation in KRAS 
or PIK3CA concomitant to EGFR gene copy number gain (Table 8). 
In details, three patients had a FISH+ profile and KRAS mutation (cases #29, 
#37,#57), and three patients had a FISH+ profile and PIK3CA mutation in 


























Molecular profile of SCAC patients. A: amplification, D: disomy, FISH+: 4 copies of EGFR in 
40% of cells or amplification, FISH-: 4 copies in <40% of cells, loss: loss of chromosome 




41 D FISH- WT WT WT WT
42 LP FISH- WT WT WT WT
43 HP FISH+ WT WT WT WT
44 LP FISH+ WT WT WT WT
45 D FISH- WT WT WT WT
46 LP FISH+ WT WT WT WT
47 LP FISH+ WT WT WT WT
48 D FISH- WT WT WT WT
49 loss FISH- WT WT WT WT
50 HP FISH+ WT WT WT WT
51 HP FISH+ WT WT WT WT
52 HP FISH+ WT WT WT WT
53 LP FISH- WT WT WT WT
54 A FISH+ WT WT WT WT
55 D FISH- WT WT E545K WT
56 D FISH- WT WT WT WT
57 LP FISH+ G12D WT n.e. n.e.
58 LP FISH- WT WT n.e. n.e.
59 D FISH- n.e. WT n.e. n.e.
60 D FISH- WT WT WT WT
61 LP FISH- WT WT WT WT
62 A FISH+ WT WT WT WT
63 D FISH- WT WT WT WT
64 D FISH- WT WT WT WT
65 LP FISH- WT WT WT H1047R
66 LP FISH+ WT WT WT WT
67 D FISH- WT WT E545K WT
68 LP FISH- WT WT WT WT
69 HP FISH+ WT WT WT WT
70 D FISH- G12D WT WT WT
71 D FISH- WT WT WT WT
72 D FISH- WT WT WT WT
73 D FISH- WT WT WT WT
74 LP FISH- WT WT E542K WT
75 D FISH- WT WT WT WT
76 LP FISH- WT WT WT WT
77 D FISH- WT WT WT WT
78 LP FISH+ WT WT WT WT
79 D FISH- WT WT WT WT
80 D FISH- WT WT WT WT
81 HP FISH+ WT WT WT WT
82 LP FISH+ WT WT E545K WT
83 HP FISH+ WT WT WT WT
84 D FISH- WT WT WT WT
85 LP FISH- WT WT WT WT
86 n.e. n.e. WT WT WT WT
87 LP FISH+ WT WT WT WT
88 LP FISH- WT WT WT WT
89 HP FISH+ WT WT WT WT
90 LP FISH+ WT WT WT WT
91 HP FISH+ WT WT WT WT
92 n.e. n.e. WT WT WT WT
93 A FISH+ WT WT WT WT
 PIK3CA EX 9 PIK3CA EX 20# FISH EGFR  KRAS BRAF























Molecular profile of SCAC patients. A: amplification, D: disomy, FISH+: 4 copies of EGFR in 
40% of cells or amplification, FISH-: 4 copies in <40% of cells, loss: loss of chromosome 











mut mut mut mut
KRAS PIK3CA PIK3CA ex9 PIK3CA ex20 EGFR* EGFR** FISH* FISH**
1 0.69 1 1 0.5 0.38 0.13 0.67
1 0.59 1 1 1 0.14 0.62 0.13
1 1 1 1 0.57 0.63 1 0.29
1 0.4 0.7 0.7 0.48 0.49 0.65 0.71
Keratinization 1 1 1 1 0.14 1 1 0.49
- 1 1 1 1 0.64 0.15 0.48
- - - - 1 0.54 0.35 0.82
PIK3CA ex9 - - - 1 1 0.74 0.74 0.92







4.5 CORRELATION BETWEEN CLINICAL PATHOLOGICAL AND 
MOLECULAR RESULTS 
Analysis of correlation among clinical pathological features (age, sex, G and 
keratinization) revealed that patients age was associated with tumor G (both 
for patients older than 50 and older than 40 years) (p< 0.01 and p= 0.04, 
respectively). G was also associated with keratinization (p< 0.01). A trend of 







P values of clinical-pathological correlation by Fisher’s Exact Test. Significant values in bold. 
 
No significant correlation has been found between clinical pathological 
features and EGFR gene status (presence of A, D, FISH+ or FISH- profile) 
as detected by FISH and molecular alterations in KRAS and PIK3CA (both in 








P values of molecular correlation by Fisher’s Exact Test. EGFR*: A vs. not A, EGFR**: D vs. 
not D, FISH*: FISH+ vs. FISH-, FISH**: L vs. D vs. LP vs. HP vs. A. 
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5 DISCUSSION AND CONCLUSION 
 
SCAC is a rare disease, representing 1.5% of all the gastrointestinal tumors 
(Martin FT. et al, 2009). HPV is detected in the majority of SCAC patients 
and HR-HPV infection is considered the initiating event in anal epithelial 
transformation (Gervaz P. et al, 2006). 
Patients with primary SCAC are traditionally managed with chemoradiation, 
which results in complete response in up to 90% of cases. In non-responders 
or recurrent patients, salvage APR, that results in a permanent colostomy, is 
recommended (Gervaz P. et al, 2008; Czito BG. et al, 2009; Meyer J. et al, 
2010). To overcome the severe side effects of this surgical procedure new 
therapeutic options are being evaluated. A very promising approach is 
represented by treatments able to inhibit molecules that are fundamental for 
tumor growth, the so called targeted therapies.  
In the past few years, EGFR, a TK receptor that finely regulates cell 
proliferation and cell survival (through the RAS/RAF/MEK/ERK and 
PI3K/PTEN/AKT pathways), has gained increased importance due to its role 
as a target for tailored treatment. Recently the anti-EGFR monoclonal 
antibody cetuximab has been FDA and EMA approved as therapy for  
different tumors, both squamous and adeno-carcinomas, such as advanced 
or recurrent HNSCC and mCRC (Gazdar AF., 2010; Kendall A. et al, 2010; 
Tejani MA. et al, 2010). 
Similarly, in order to overcome failure of conventional therapies and the 
consequences of the ablative surgery, the use of cetuximab has been 
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proposed in SCAC, on the basis of some molecular features of this cancer, 
such as EGFR protein overexpression and gene copy number gain, which 
have been described in a significant proportion of cases (Le LH. et al, 2005; 
Alvarez G. et al, 2006; Walker F. et al, 2009; Van Damme N. et al, 2010). 
 
At the moment, only sporadic studies have investigated the use of cetuximab 
in SCAC, reporting activity in very few patients affected by a refractory or 
metastatic disease. Moreover, little is known in SCAC not only about EGFR 
gene copy number gain, that seems to be a predictive marker of cetuximab 
efficacy, but also about EGFR-downstream members alterations (KRAS, 
PIK3CA and BRAF mutations), which are known to be markers of resistance 
to anti-EGFR therapies in patients affected by mCRC (Moroni M. et al, 2005; 
Lievre A. et al, 2006; Benvenuti S. et al, 2007; Frattini M. et al, 2007). 
Phan and colleagues, evidenced a female patient with refractory SCAC who 
achieved an excellent response to the combination of cetuximab and 
irinotecan after having failed single-agent irinotecan (Phan LK. et al, 2007). 
Lukan reported a disease control in 5 out of 7 patients with metastatic SCAC 
treated with cetuximab, in first or subsequent lines instead of cisplatin-based 
therapy, and interesting revealed that all the 5 responders patients were 
characterized by absence of mutations in KRAS gene, in contrast to both 
patients with progressive disease that showed KRAS mutations (Lukan N. et 
al, 2009). Our group described about one refractory SCAC patient that 
benefited from the same combination and that showed EGFR gene copy 
number gain and absence of mutations in KRAS gene (De Dosso S. et al, 
2010). Finally, Saif described a good response after cetuximab or 
panitumumab in 3 cases of refractory SCAC (Saif M. et al, 2011). 
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These anecdotic findings reproduce those obtained in mCRC, thus 
supporting the importance of EGFR investigation, and confirming the role of 
KRAS as a putative predictive marker of non-response to cetuximab also in 
SCAC. Similarly, they suggest the possible role of other EGFR downstream 
members, such as PIK3CA and BRAF, in affecting the efficacy of anti-EGFR 
agents also in SCAC (Mao C. et al, 2009; Bardelli A. et al, 2010). 
The only study investigating PIK3CA in SCAC identified 5 patients with 
mutations out of 127 patients (5%) (Patel H. et al, 2007).  
 BRAF mutations in SCAC have not been investigated yet, thus indicating the 
need of additional studies on this issue. 
Therefore, we investigated EGFR and its downstream pathway in the same 
cohort of SCAC by analyzing EGFR gene status by FISH and KRAS, BRAF 
and PIK3CA mutations by sequencing. 
 
In this study we analyzed 93 patients affected by SCAC. 
In line with literature data, the great majority of them (96%) showed 
integration of the HPV virus, thus supporting the hypothesis that infection is 
one of the driving events in the tumorigenesis of this cancer. 
More than thirty percent of the investigated patients were characterized by 
EGFR gene copy number gain (i.e. FISH+, 37%), confirming the very few 
published studies reporting a rate of polysomy ranging from 9% to 33% (Le 
LH. et al, 2005; Alvarez G. et al, 2006; Walker F. et al, 2009; Van Damme N. 
et al, 2010). Interestingly, we documented for the first time the presence of 
EGFR gene amplification in four SCAC patients. Of these, three patients 
showed high level of gene amplification with large clusters of signals in all the 
tissue, whereas one patient showed a low level of gene amplification in 
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different tumor areas, thus probably suggesting that different biological 
mechanisms might be involved in the activation of this oncogene in SCAC. 
Concerning EGFR-downstream members, we detected KRAS gene 
mutations in four patients (corresponding to 4% of our cohort), confirming 
that this alteration may occur in a subgroup of SCAC, as reported by Lukan 
and coauthors (Lukan N. et al, 2009), and that is not a rare event, as 
indicated in two recent studies that did not find any KRAS mutation out of a 
total of 82 investigated SCAC patients (Zampino MG. et al, 2009; Van 
Damme N. et al, 2010). 
Investigation in PIK3CA gene sequence identified a group of 13 mutated 
patients out of 89 (15%) analyzable SCAC. The majority of these 
(10/13=77%) presented a mutation in exon 9, whereas only 3 cases were 
mutated in exon 20. Distinction about the site of mutation in PIK3CA gene is 
extremely important. It has been recently demonstrated in mCRC that 
patients with mutation in exon 20 of PIK3CA are resistant to cetuximab 
treatment, whereas patients with mutation in exon 9 have the same likelihood 
of response to cetuximab that have patients with PIK3CA wild type gene (De 
Roock W. et al, 2010); therefore in our cohort we could enumerate only 3 
patients having a PIK3CA mutation that is a putative predictive marker of 
resistance to EGFR-targeted therapies. 
Our results about PIK3CA mutations showed some discrepancies when 
compared with data obtained in the lonely published study concerning 
PIK3CA mutation analyses in SCAC (Patel H. et al, 2007). Differences were 
related to the frequency of mutations and to the type of mutations (exon 9 vs. 
exon 20). In details, Patel and colleagues found PIK3CA mutations in 5 
patients out of 127 SCAC, with a rate of mutation lower than what has been 
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obtained in our study (4% vs. 16%); also they found that the majority of 
mutations involved exon 20 (4 patients) rather than exon 9 (1 patient), the 
opposite of our results (10 patients with mutation in exon 9 and 3 patients in 
exon 20). Nevertheless, even if some epidemiological effects may play a role, 
our results are similar with general data concerning frequency of PIK3CA 
mutations in SCC at other sites, that are in a range of 6-10% (Kozaki K. et al, 
2006; Mori R. et al, 2008; Murugan AK. et al, 2008; Akagi I. et al, 2009).  
Finally, in this work we investigated for the first time the presence of BRAF 
gene mutation in SCAC patients. Our findings indicated absence of mutations 
in BRAF gene, similarly to other SCC, where it is reported as a rare event 
(<3% of patients), thus suggesting that probably this gene plays a minor role 
(if any) in SCAC (Cosmic, Catalogue of Somatic Mutation: http://www. 
sanger.ac.uk/genetics/CGP/cosmic/). Further studies investigating larger 
series of SCAC patients are needed to confirm and validate this hypothesis. 
Overall, our results revealed that: i) chromosome 7 polysomy seems to be 
the principal mechanisms of EGFR deregulation, whereas gene amplification 
is rare, but not absent, as stated at the moment in literature; ii) KRAS and 
PIK3CA mutations may be identified in a subgroup of SCAC patients; iii) 
BRAF does not play a relevant role in SCAC tumorigenesis.  
 
In conclusion, our study characterized in the same cohort of SCAC the 
deregulation of EGFR and of its downstream members. Assuming that 
evidences obtained from mCRC and HNSCC are valid for SCAC (hypothesis 
that is confirmed at the moment in some anecdotic SCAC treated with 
cetuximab) around 30% of SCAC patients have a proficient molecular profile 
to be addressed to EGFR-targeted therapies (Phan LK. et al, 2007; Lukan N. 
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et al, 2009; De Dosso S. et al, 2010; Saif M. et al, 2011). This subgroup is 
represented by SCAC patients whit EGFR gene copy number gain (FISH+), 
absence of mutation in KRAS, absence of mutation in PIK3CA or mutation in 
PIK3CA exon 9 (Figure 9). On these bases, it is strongly recommended that, 
in the future, prospective clinical trials should be proposed with evidences for 










Algorithm of patients selection based on cytogenetical and molecular profile. 
In green SCAC patients who are likely to benefit from anti-EGFR targeted therapy; in red 
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